A phase 1 Zanidatamab in combination with Tukysa (tucatinib) and capecitabine for the treatment of HER2-positive breast cancer patients with locally advanced (unresectable) and/or metastatic disease
Latest Information Update: 02 Aug 2021
At a glance
- Drugs Capecitabine (Primary) ; Tucatinib (Primary) ; Zanidatamab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions
- 02 Aug 2021 New trial record
- 28 Jul 2021 According to a Zymeworks media release, first patient has been dosed in this study.